Additionally, clinical diagnostic criteria for PSP–Richardson’s syndrome and amyloid-negative CBS (here called CBD) were used to select a clinical cohort with likely a 4R-tauopathy as the underlying pathological diagnosis. This evidence concerns the gene CBS and Classical progressive supranuclear palsy.